Pyoderma Gangrenosum

Also known as: Pyoderma gangrenous / Pyoderma gangenosum / Phagedenic pyoderma

DrugDrug NameDrug Description
DB00051AdalimumabAdalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor [A39984], [A39999]. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA [A39983]. This drug is frequently known as _Humira_. It is produced by recombinant DNA technology using a mammalian cell expression system. This drug is available in a prefilled syringe form and convenient pen form for subcutaneous self-administered doses [A39983]. A new biosimilar to adalimumab, named _adalimumab-adaz_, was approved by the FDA on October 31, 2018. This biosimilar is known as _Hyrimoz_, and is a trademark of Novartis AG [L4799].
DB00005EtanerceptDimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids.
DB00798GentamicinA complex of three different closely related aminoglycoside sulfates, Gentamicins C1, C2, and C1a, obtained from Micromonospora purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit protein synthesis (genetic translation).
DB00864TacrolimusTacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condition vitiligo. It was discovered in 1984 from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis. Tacrolimus is chemically known as a macrolide. It reduces peptidyl-prolyl isomerase activity by binding to the immunophilin FKBP-12 (FK506 binding protein) creating a new complex. This FKBP12-FK506 complex inhibits calcineurin which inhibits T-lymphocyte signal transduction and IL-2 transcription.
DrugDrug NameTargetType
DB00051AdalimumabTumor necrosis factortarget
DB00005EtanerceptTumor necrosis factortarget
DB00005EtanerceptLymphotoxin-alphatarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00005EtanerceptComplement C1r subcomponenttarget
DB00005EtanerceptComplement C1q subcomponent subunit Atarget
DB00005EtanerceptComplement C1q subcomponent subunit Btarget
DB00005EtanerceptComplement C1q subcomponent subunit Ctarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00005EtanerceptComplement C1s subcomponenttarget
DB00005EtanerceptHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00005EtanerceptTumor necrosis factor receptor superfamily member 1Btarget
DB00798Gentamicin30S ribosomal protein S12target
DB00798Gentamicin16S rRNAtarget
DB00798GentamicinLow-density lipoprotein receptor-related protein 2target
DB00798GentamicinSolute carrier family 22 member 6transporter
DB00798GentamicinNH(3)-dependent NAD(+) synthetasetarget
DB00798GentamicinDihydrofolate reductasetarget
DB00864TacrolimusPeptidyl-prolyl cis-trans isomerase FKBP1Atarget
DB00864TacrolimusCytochrome P450 3A4enzyme
DB00864TacrolimusCytochrome P450 3A5enzyme
DB00864TacrolimusCytochrome P450 3A7enzyme
DB00864TacrolimusMultidrug resistance protein 1transporter
DB00864TacrolimusATP-binding cassette sub-family A member 5transporter
DB00864TacrolimusSerum albumincarrier
DB00864TacrolimusAlpha-1-acid glycoprotein 1carrier
DB00864TacrolimusSolute carrier organic anion transporter family member 1B1transporter
DrugDrug NamePhaseStatusCount
DB09029Secukinumab1 / 2Recruiting1
DB00051Adalimumab2Withdrawn2
DB06168Canakinumab2Completed1
DB14766Etrasimod2Terminated1
DB12119Gevokizumab2Completed1
DB11569Ixekizumab2Completed1
DB00051Adalimumab3Active Not Recruiting1
DB12119Gevokizumab3Terminated3
DB00065InfliximabNot AvailableCompleted1